Posts tagged: eae

EBioMedicine. 2019 Sep 3. pii: S2352-3964(19)30574-2. doi: 10.1016/j.ebiom.2019.08.052. Fovet CM1, Stimmer L1, Contreras V2, Horellou P2, Hubert A3, Seddiki N3, Chapon C2, Tricot S2, Leroy…

BBA Clin. 2015 Jan 15;3:126-34. doi: 10.1016/j.bbacli.2015.01.003. eCollection 2015. Kariya Y1, Kariya Y1, Saito T1, Nishiyama S2, Honda T3, Tanaka K4, Yoshida M5, Fujihara K2,…

Research Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders Klaus Lehmann-Horn , Eva Schleich , Deetje Hertzenberg , Alexander Hapfelmeier , Tania Kuempfel , Nikolas von Bubnoff , Reinhard Hohlfeld , Achim Berthele , Bernhard Hemmer and Martin S Weber ? For all author emails, please log on . Journal of Neuroinflammation 2011, 8 :146? doi:10.1186/1742-2094-8-146 Published: 26 October 2011 Abstract (provisional) Background Clinical trials evaluating anti-CD20-mediated B-cell depletion in multiple sclerosis (MS) and neuromyelitis optica (NMO) generated encouraging results.

Aquaporin-4 (AQP4) deficiency in mice reduces neuroinflammation in experimental autoimmune encephalomyelitis (EAE) produced by active immunization with myelin oligodendrocyte glycoprotein peptide (MOG).

Objective: Clinical studies indicate that anti-CD20 B-cell depletion may be an effective multiple sclerosis (MS) therapy. We investigated mechanisms of anti-CD20-mediated immune modulation using 2 paradigms of experimental autoimmune encephalomyelitis (EAE). Methods: Murine EAE was induced by recombinant myelin oligodendrocyte glycoprotein (rMOG), a model in which B cells are considered to contribute pathogenically, or MOG peptide (p)35-55, which does not require B cells.